A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics
Rapid innovation in (epi)genetics and biomarker sciences is driving a new drug development and product development pathway, with the personalized medicine era dominated by biologic therapeutics and companion diagnostics. Companion diagnostics (CDx) are tests and assays that detect biomarkers and spe...
Main Authors: | Dee eLuo, James A Smith, Nick A Meadows, Katie eManescu, Kim eBure, Benjamin eDavies, Rob eHorne, David L DiGiusto, David A Brindley |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-01-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fgene.2015.00357/full |
Similar Items
-
Corrigendum: A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics
by: Dee eLuo, et al.
Published: (2016-06-01) -
Lysophosphatidic Acid Signaling in Cancer
by: David N. Brindley
Published: (2020-12-01) -
Market Access Advancements and Challenges in “Drug-Companion Diagnostic Test” Co-Development in Europe
by: Ildar Akhmetov, et al.
Published: (2015-06-01) -
Major research project : "we were in one place and the ethics committee in another" : trainee clinical psychologists' experiences of research ethics processes
by: Brindley, Rob
Published: (2012) -
Aligning the Economic Value of Companion Diagnostics and Stratified Medicines
by: Edward D. Blair, et al.
Published: (2012-11-01)